近日（10月10日），根据CDE官网公示，盛禾生物ISH0613已经向NMPA申报IND，并得到受理。根据该公司官网显示，ISH0613这款管线的靶点未知，适应症为SLE（系统性红斑狼疮），靶向效果可抑制B细胞激活及IFNα分泌，采用的是该公司的抗体细胞因子融合蛋白平台（AIC）。根据招股书显示，该药物原定于2024年Q2向NMPA提交IND，如今延期了一年。本文简单推测ISH0613可能是一款...
Source Link近日（10月10日），根据CDE官网公示，盛禾生物ISH0613已经向NMPA申报IND，并得到受理。根据该公司官网显示，ISH0613这款管线的靶点未知，适应症为SLE（系统性红斑狼疮），靶向效果可抑制B细胞激活及IFNα分泌，采用的是该公司的抗体细胞因子融合蛋白平台（AIC）。根据招股书显示，该药物原定于2024年Q2向NMPA提交IND，如今延期了一年。本文简单推测ISH0613可能是一款...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.